ASX - Delayed Quote AUD

Cyclopharm Limited (CYC.AX)

Compare
1.9500
-0.0500
(-2.50%)
As of 2:24:31 PM GMT+11. Market Open.
Loading Chart for CYC.AX
DELL
  • Previous Close 2.0000
  • Open 2.0500
  • Bid 1.9600 x --
  • Ask 2.0200 x --
  • Day's Range 1.9500 - 2.0600
  • 52 Week Range 1.3300 - 2.3200
  • Volume 58,141
  • Avg. Volume 60,841
  • Market Cap (intraday) 216.717M
  • Beta (5Y Monthly) 0.72
  • PE Ratio (TTM) --
  • EPS (TTM) -0.1000
  • Earnings Date Feb 26, 2025 - Mar 3, 2025
  • Forward Dividend & Yield 0.01 (0.74%)
  • Ex-Dividend Date Sep 1, 2023
  • 1y Target Est 2.95

Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. The company operates through Technegas and Molecular Imaging segments. The Technegas segment offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. This segment also distributes products to the diagnostic imaging sector. The Molecular Imaging segment provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders, and cardiac diseases. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is headquartered in Kingsgrove, Australia.

www.cyclopharm.com

87

Full Time Employees

December 31

Fiscal Year Ends

Recent News: CYC.AX

View More

Performance Overview: CYC.AX

Trailing total returns as of 1/16/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

CYC.AX
23.03%
S&P/ASX 200 [XJO]
1.97%

1-Year Return

CYC.AX
5.41%
S&P/ASX 200 [XJO]
12.21%

3-Year Return

CYC.AX
9.03%
S&P/ASX 200 [XJO]
12.52%

5-Year Return

CYC.AX
57.64%
S&P/ASX 200 [XJO]
18.15%

Compare To: CYC.AX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CYC.AX

View More

Valuation Measures

As of 1/15/2025
  • Market Cap

    222.27M

  • Enterprise Value

    200.28M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    8.14

  • Price/Book (mrq)

    4.67

  • Enterprise Value/Revenue

    8.61

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -38.72%

  • Return on Assets (ttm)

    -15.37%

  • Return on Equity (ttm)

    -22.59%

  • Revenue (ttm)

    24.06M

  • Net Income Avi to Common (ttm)

    -9.32M

  • Diluted EPS (ttm)

    -0.1000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    28.89M

  • Total Debt/Equity (mrq)

    11.72%

  • Levered Free Cash Flow (ttm)

    -6.99M

Research Analysis: CYC.AX

View More

People Also Watch